Ansella Therapeutics is pioneering the use of biomimetic sciences to develop innovative therapeutics aimed at improving women's health, particularly in addressing conditions such as vaginal dryness, dyspareunia, and vaginal mucositis. The company’s approach is centered around the Biomyme V® platform, which is designed to create vaginal formulations that closely mimic the natural biological environment of the vagina. This platform utilizes an isotonic, pH-balanced formulation that incorporates ingredients like lactic acid and glycogen, which are compatible with the vaginal microbiome. By focusing on the unique biophysiology of the vaginal mucosa, Ansella aims to enhance the efficacy and safety of its products, ensuring they support rather than disrupt the natural processes of the body.

The Biomyme V platform not only addresses the symptoms of vulvovaginal atrophy (VVA) but also aims to restore the underlying physiological conditions that contribute to vaginal health. The formulations are designed to maintain cell integrity and promote the production of lactic acid by commensal bacteria, which is essential for a healthy vaginal environment. Additionally, the inclusion of cholesterol in the formulations enhances drug delivery by optimizing the fluidity and permeability of cell membranes, allowing for more effective absorption of therapeutic agents. This innovative approach positions Ansella Therapeutics at the forefront of developing targeted treatments that align with the body's natural biology, ultimately improving healthcare outcomes for women.

United States

Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes.

Ansella Therapeutics

Company Details